Page 1 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Septal reduction therapy  
- Septal alcohol ablation  
- Implantable cardioverter‑defibrillator  
- Cardiac myosin inhibitors  
- Diastolic dysfunction  
- Systolic dysfunction  
- Ventricular arrhythmias  
- Atrial fibrillation  
- Family screening  
- Genetics  
- Sarcomeric genes  
- Risk stratification  
- Sports  
- Sudden cardiac death  
- Exercise stress testing  
- Rhythm monitoring  
- Shared decision‑making  
- Pregnancy  
- Cardiovascular magnetic resonance imaging  
- Echocardiography  
- Athlete  
- Physical activity  
- Occupation  

Page 2 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract (LVOT) Obstruction  
- Diastolic Dysfunction  
- Mitral Regurgitation  
- Myocardial Ischemia  
- Autonomic Dysfunction  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Pharmacologic Management of Symptomatic Patients with Obstructive HCM  
- Invasive Treatment for Obstructive HCM (e.g., surgical myectomy, alcohol septal ablation)  
- Nonobstructive HCM with Preserved Ejection Fraction (EF)  
- HCM and Advanced Heart Failure (HF)  
- HCM and Atrial Fibrillation (AF)  
- HCM and Ventricular Arrhythmias  
- Echocardiography (ECHO)  
- Cardiovascular Magnetic Resonance (CMR) Imaging  
- Cardiac Computed Tomography (CT)  
- Heart Rhythm Assessment (electrocardiography, Holter, event monitoring)  
- Angiography and Invasive Hemodynamic Assessment  
- Exercise Stress Testing (treadmill, bicycle)  
- Genetics and Family Screening for HCM  
- Genotype‑Positive, Phenotype‑Negative Individuals  
- SCD Risk Assessment in Adults with HCM  
- SCD Risk Assessment in Children/Adolescents with HCM  
- Patient Selection for ICD Placement  
- Device Selection Considerations (ICD, CRT‑D, pacemaker)  
- Lifestyle Considerations for HCM (Recreational Physical Activity, Competitive Sports)  
- Occupational Considerations for Patients with HCM  
- Pregnancy Management in HCM  
- Management of Comorbidities in HCM  
- Evidence Gaps and Future Directions (e.g., refining diagnosis, new therapies, risk stratification, arrhythmia management, genetic architecture)

Page 3 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Obstructive HCM  
- Non‑obstructive HCM  
- Exercise stress testing  
- Septal reduction therapy (SRT)  
- Myosin inhibitor (e.g., mavacamten)  
- Disopyramide  
- β‑blocker  
- Nondihydropyridine calcium channel blocker  
- Anticoagulation  
- Valsartan  
- NYHA functional class III–IV  
- Risk score / risk factors  
- Systolic dysfunction (LVEF < 50 %)  
- Pregnancy (in HCM)  
- Recreational physical activity  
- Competitive sports



Page 4 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac myosin inhibitors  
- Mavacamten  
- Septal myectomy  
- Alcohol septal ablation  
- Atrial fibrillation  
- Oral anticoagulation  
- Direct‑acting oral anticoagulants (DOACs)  
- Warfarin  
- CHA₂DS₂‑VASc score  
- Exercise stress testing  
- Exercise tolerance  
- Genetic testing (HCM‑associated variants)  
- Family screening (first‑degree relatives)  
- Risk stratification (pediatric and adult)  
- Pediatric risk calculator  
- Ventricular arrhythmia  
- Stroke risk (HCM patients)  
- Ambulatory telemetry  
- Metabolic equivalents of task (METs)  
- Cardiac contractility  
- Actin‑myosin interaction inhibition  
- Cardiac imaging (serial imaging for HCM)

Page 5 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic Cardiomyopathy  
- Cardiovascular disease  
- Cardiovascular health  
- Cardiovascular care  

These terms are central to the discussion of heart disease in the provided text.

Page 6 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy  
- Subvalvular stenosis  
- Coronary ischemia  
- Atrial fibrillation  
- Stroke volume  
- Sudden cardiac death  
- Cardiac transplant  
- Diagnostic imaging  
- Echocardiography  
- Magnetic resonance imaging (MRI)  
- Nuclear magnetic resonance imaging (NMRI)  
- Computed tomographic angiography (CTA)  
- Genetic testing for cardiac conditions  
- Guideline‑directed management and therapy (GDMT)  
- Cardiac drugs (pharmacological treatment regimens)  
- Cardiac devices (implantable devices)  
- Procedural treatments (surgical or interventional procedures)  
- Clinical evaluation of cardiac patients  
- Dosage and medication interactions  
- Contraindications in cardiovascular therapy  

These terms capture the core cardiovascular concepts and clinical focus discussed in the guideline.

Page 7 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

- Hypertrophic cardiomyopathy (HCM)  
- Heart failure (HF)  
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Sudden cardiac death (SCD)  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Left ventricular assist device (LVAD)  
- Mitral regurgitation (MR)  
- Systolic anterior motion (SAM)  
- Subclinical atrial fibrillation (SCAF)  
- Nonsustained ventricular tachycardia (NSVT)  
- Left bundle branch block (LBBB)  
- Late gadolinium enhancement (LGE)  
- Ejection fraction (EF / LVEF)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiopulmonary exercise test (CPET)  
- Transesophageal echocardiogram (TEE)  
- Transthoracic echocardiogram (TTE)  
- Guideline‑directed medical therapy (GDMT)  
- Extended septal myectomy (ESM)  
- Septal reduction therapy (SRT)  
- Metabolic equivalent (MET)  
- Direct‑acting oral anticoagulants (DOAC)  
- Right ventricular (RV)  
- Left ventricular (LV)  
- New York Heart Association (NYHA)

Page 8 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Idiopathic hypertrophic subaortic stenosis  
- Hypertrophic obstructive cardiomyopathy  
- Left ventricular (LV) outflow tract obstruction (LVOTO)  
- Left ventricular (LV)  
- Heart failure (HF)  
- Genetic testing for HCM  
- Racial and ethnic disparities in HCM prevalence  
- Female under‑diagnosis of HCM  
- Social determinants of health influencing cardiac disease  
- Structural inequities in access to cardiac specialists  
- Diagnostic testing for HCM  
- Clinical strategies and interventions for cardiac disease  
- Class of Recommendation (clinical guideline classification)  
- Level of Evidence (clinical research grading)

Page 9 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Hypertrophy (LVH)  
- Left Ventricular (LV) wall thickness  
- RASopathies  
- Mitochondrial myopathies  
- Glycogen storage disease  
- Lysosomal storage disease  
- Fabry disease  
- Amyloidosis  
- Sarcoid (sarcoidosis)  
- Danon cardiomyopathy  
- Athlete’s heart  
- Hypertensive cardiomyopathy  
- Left‑sided obstructive lesions  
- Valvular stenosis  
- Subvalvular stenosis  
- Antero‑apical infarction  
- Stress cardiomyopathy  
- 2‑D echocardiography  
- Cardiovascular magnetic resonance (CMR)  
- Wall thickness ≥15 mm  
- Body surface area–adjusted z‑score  
- Standard deviations above the mean  
- Sarcomere gene  
- Pathogenic variant  
- Likely pathogenic variant  
- Basal anterior septum  
- Anterior free wall  
- Systolic anterior motion (SAM)  
- Hypertrophied papillary muscles  
- Apically displaced papillary muscles  
- Myocardial crypts  
- Anomalous insertion of papillary muscles  
- Elongated mitral valve leaflets  
- Myocardial bridging  
- Right ventricular hypertrophy  
- Sarcomere proteins  
- Abnormal electrocardiogram (ECG)  
- Phenotype  
- Genotype‑positive / phenotype‑negative  
- Diagnostic challenges  
- Pathophysiologic mechanisms  
- Natural history  
- Treatment strategies

Page 10 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular ejection fraction (LVEF)  
- Myocardial fibrosis  
- Diastolic dysfunction  
- Systolic dysfunction  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular arrhythmia  
- Atrial fibrillation (AF)  
- Thromboembolic stroke  
- Heart failure (HF)  
- Myocardial ischemia  
- Left ventricular outflow tract obstruction (LVOTO)  
- Mitral regurgitation (MR)  
- Small vessel ischemia  
- Intramural coronary artery abnormalities  
- Elongated mitral valve leaflets  
- Congenital anomalies of the submitral valve apparatus  
- Cardiac sarcomere genes  
- Sarcomere‑related structures  
- Beta‑myosin heavy chain 7 (MYH7)  
- Myosin‑binding protein C3 (MYBPC3)  
- TNNI3 (troponin I type 3)  
- TNNT2 (troponin T type 2)  
- TPM1 (tropomyosin 1)  
- MYL2 (myosin light chain 2)  
- MYL3 (myosin light chain 3)  
- ACTC1 (alpha‑actin 1)  
- Pathogenic sarcomeric variant  
- Likely pathogenic variant  
- Nonfamilial HCM  
- Monogenic disease  
- Polygenic susceptibility  
- Genetics‑mediated risk stratification  
- Noninvasive risk markers  
- Cardiometabolic risk factors  
- Obesity  
- Hypertension  
- Diabetes mellitus  
- Obstructive sleep apnea  
- Lifestyle modification (risk factor reduction)  
- Cardiovascular therapies  
- Interventional procedures (e.g., septal reduction)  
- Clinical guidelines for HCM management  
- Outcome prediction in HCM patients  
- Adverse event risk (mortality, HF, stroke, arrhythmia)  
- Disease‑related morbidity and mortality in adults  
- Dynamic LVOTO  
- Autonomic dysfunction  
- Metabolic and energetic abnormalities in HCM.

Page 11 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Subaortic Membrane (SAM) of the mitral valve  
- Peak LVOT gradient  
- Intracavitary pressure  
- Diastolic dysfunction  
- LV compliance  
- Microvascular ischemia  
- Sarcomere gene variant carriers  
- Restrictive physiology  
- Atrial fibrillation (AF)  
- Mitral regurgitation (MR)  
- Leaflet abnormalities (excessive leaflet length, anomalous papillary muscle insertion)  
- Mid‑to‑late systolic jets  
- Central and anterior jets  
- Septal reduction therapy (SRT)  
- Intrinsic coronary flow reserve (CRF)  
- Coronary atherosclerosis  
- LV apical aneurysm  
- Heart failure (HF)  
- Stroke  
- Ventricular arrhythmias  
- Myocardial bridging  
- Autonomic dysfunction  
- Heart rate recovery  
- Inappropriate vasodilatation  
- Blood pressure response to exercise  
- Epicardial coronary artery compression  
- Intramural arterioles (density)  
- Myocardial oxygen supply‑demand mismatch  
- Systolic dysfunction  
- Ventricular preload, afterload, contractility  
- Valsalva maneuver  
- Dobutamine stress testing  
- Echocardiographic assessment  
- Invasive LVOT gradient measurement.

Page 12 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- HCM  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Septal Reduction Therapy (SRT)  
- Invasive SRT  
- Implantable Cardioverter‑Defibrillator (ICD) implantation  
- Genetic testing  
- Genetic counseling  
- Shared decision‑making  
- Multidisciplinary HCM centers  
- Comprehensive HCM centers  
- Primary HCM centers  
- Advanced therapies for relief of LVOTO  
- High‑intensity or competitive exercise  
- Mitral valve replacement  
- Morbidity  
- Mortality  
- Clinical outcomes  
- Risk assessment  
- Benefit assessment  
- Diagnostic testing  
- Surveillance testing  
- Care coordination  
- Patient and caregiver goals  
- Lifestyle and activity modification  
- Referral pathways  
- Cardiac management decisions  

Page 13 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Comprehensive HCM center  
- Primary HCM center  
- Septal reduction therapy (SRT)  
- Invasive SRTs (myectomy, alcohol septal ablation)  
- Catheter ablation  
- Ventricular tachyarrhythmias  
- Atrial tachyarrhythmias  
- Advanced heart failure (HF) therapies  
- Heart transplant  
- Implantable cardioverter‑defibrillator (ICD)  
- Genetic counseling  
- Sports participation counseling  
- Clinical diagnosis of HCM  
- Physical examination  
- Family history (3‑generation)  
- Cardiac murmur  
- Transthoracic echocardiography (TTE)  
- Advanced echocardiographic imaging  
- Left ventricular outflow tract obstruction (LVOTO)  
- Latent LVOTO detection  
- Echocardiography‑guided SRT  
- Cardiovascular magnetic resonance (CMR) imaging  
- Invasive LVOTO evaluation  
- Coronary angiography  
- Stress testing for LVOTO or advanced HF consideration  
- Risk stratification for sudden cardiac death (SCD)  
- Adult ICD decision‑making (COR 1 & 2a)  
- Pediatric ICD decision‑making (COR 2b)  
- ICD implantation in adults and children  
- Atrial fibrillation (AF) management  
- Stroke prevention in AF  
- AF catheter ablation  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Cardiac resynchronization therapy (CRT)  
- Pharmacologic therapy for HCM  
- Invasive management of obstructive HCM  
- Mitral valve replacement (within 1 year of procedure)  
- Residual mitral regurgitation (moderate or greater)  
- Repeat procedure rate for SRTs  
- Symptomatic improvement (≥1 NYHA functional class)  
- Rest or provoked left ventricular outflow tract (LVOT) gradient <50 mm Hg  
- Left anterior descending (LAD) artery  
- Pacemaker implantation for post‑operative complete heart block  
- NYHA functional class (I–IV)

Page 14 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy (LVH)  
- Mitral valve systolic anterior motion (SAM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Mitral regurgitation (MR)  
- Fourth heart sound  
- Systolic murmur (harsh crescendo‑decrescendo)  
- Apical point of maximal impulse  
- Abnormal carotid pulse  
- Valsalva maneuver  
- Squat‑to‑stand maneuver  
- Passive leg‑raising maneuver  
- Walking test (provocative maneuver)  
- 12‑lead electrocardiogram (ECG)  
- Echocardiography (2‑D echo)  
- Comprehensive cardiac history  
- Family history (3 generations)  
- Genotype‑positive screening family member  
- Phenocopy (mimic) of HCM  
- RASopathies (e.g., neurofibromatosis, Noonan syndrome)  
- Glycogen storage diseases  
- Mitochondrial disorders  
- Anderson–Fabry disease  
- Amyloidosis (infiltrative cardiomyopathy)  
- Friedreich’s ataxia  
- Danon disease  
- Renal dysfunction  
- Infiltrative disorders  
- Metabolic acidosis  
- Newborn metabolic screening  
- Specific metabolic assays  
- Biochemical screening  
- Genetic testing  
- Neuromuscular assessment  
- Infant of mother with gestational diabetes  
- Chest pain (symptom)  
- Dyspnea (symptom)  
- Palpitations (symptom)  
- Syncope (symptom)  
- Screening intervals:  
  - Every 1–2 years (pediatric, genotype‑positive)  
  - Every 2–3 years (all other children/adolescents)  
  - Every 3–5 years (adults)  
- Screening for asymptomatic first‑degree relatives  
- Early childhood cognitive and sensory impairments (associated with phenocopies)  
- Skeletal muscle weakness or movement disorder (associated with phenocopies)  
- Peripheral neuropathy (associated with phenocopies)

Page 15 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Transthoracic Echocardiogram (TTE)  
- Transesophageal Echocardiogram (TEE)  
- Left Ventricular Outflow Tract (LVOT) Gradient  
- Dynamic LVOT Obstruction (LVOTO)  
- Mitral Regurgitation (MR)  
- Myocardial Hypertrophy  
- Systolic Dysfunction  
- Diastolic Dysfunction  
- Valvular Heart Disease (VHD)  
- Mitral Valve Anatomy and Function  
- Echocardiographic Screening in First‑Degree Relatives  
- Genotype‑Positive/Phenotype‑Negative Screening  
- Cardiac Magnetic Resonance (CMR) Imaging  
- Left Ventricular Apical Aneurysm  
- Provocative Maneuvers (Valsalva, squat‑to‑stand, standing)  
- Exercise TTE  
- Surgical Septal Myectomy  
- Alcohol Septal Ablation  
- Intracoronary Ultrasound‑Enhancing Contrast  
- Septal Perforator Injection  
- Septal Radiofrequency Therapy (SRT)  
- Wall Thickness Measurement  
- Chamber Dimension Assessment  
- Resting Peak LVOT Gradient < 50 mm Hg  
- Dynamic LVOTO Detection and Quantification  
- Phenotype Severity Assessment  
- Sudden Cardiac Death (SCD) Risk Stratification  
- Serial Follow‑up Echocardiography (every 1–2 years)  
- Non‑conclusive TTE → TEE or CMR  
- Imaging Modality for Myocardial Hypertrophy Pattern (apical, atypical, etc.)  
- Ultrasound‑Enhancing Agent Use (intravenous, intracardiac)  
- Structural Cardiac Abnormalities (mitral valve apparatus, subaortic membrane)  
- Concomitant Cardiac Abnormalities (systolic, diastolic, valvular)

Page 16 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- LVOT gradient  
- Valsalva maneuver  
- Stress echocardiography  
- Postprandial exercise  
- Exercise testing  
- Intraoperative transesophageal echocardiography (TEE)  
- Surgical myectomy  
- Mitral valve abnormalities  
- Mitral regurgitation (MR)  
- Septal hypertrophy  
- Systolic anterior motion (SAM)  
- Ventricular septal defect (VSD)  
- Aortic insufficiency (AI)  
- Left ventricular (LV) systolic function  
- LV diastolic function  
- LV strain (speckle‑track)  
- Left ventricular hypertrophy (LVH)  
- Apical hypertrophy  
- Aneurysm (LV)  
- Thrombus (LV)  
- Alcohol septal ablation  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Ultrasound‑enhancing agents  
- Family screening (first‑degree relatives)  
- Genotype‑positive, phenotype‑negative status  
- Penetrance  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac intervention (e.g., myectomy, ICD placement)  
- Hydration status  
- Diuretics  
- Vasodilators  
- Hypertension  
- Septal reduction therapy (SRT)  
- LVOT gradient reduction post‑ablation  
- Residual SAM post‑myectomy or ablation  

Page 17 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- CMR Imaging (Cardiac Magnetic Resonance Imaging)  
- LVH (Left Ventricular Hypertrophy)  
- LGE (Late Gadolinium Enhancement)  
- SCD (Sudden Cardiac Death)  
- ICD (Implantable Cardioverter‑Defibrillator)  
- LV wall thickness  
- EF (Ejection Fraction)  
- LV apical aneurysm  
- Myocardial replacement fibrosis  
- LV mass  
- LVOT (Left Ventricular Outflow Tract) obstruction  
- LV cavity dimensions  
- Pressure overload (hypertension, athletic conditioning)  
- Infiltrative cardiomyopathies (e.g., amyloid)  
- Lysosomal storage diseases  
- Glycogen storage diseases  
- Echocardiography  
- ECG (12‑lead electrocardiogram)  
- Cardiac symptoms  
- Inherited heart disease  
- Systolic dysfunction (EF < 50%)  
- Ventricular tachyarrhythmias  
- Ventricular dysfunction  
- Heart failure (HF) symptoms  
- Mitral valve structural abnormalities  
- Subvalvular apparatus abnormalities  
- Noninvasive risk markers  
- LV remodeling (ventricular cavity enlargement, wall thinning)  
- LV segment involvement  
- Quantification of LGE (≥ 15 % LV mass)  
- Diagnostic clarification  
- Risk stratification  
- Preprocedural planning for surgical or catheter‑based interventions (SRT)

Page 18 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract (LVOT)  
- Septal myectomy  
- Percutaneous alcohol ablation  
- Cardiac Magnetic Resonance (CMR) imaging  
- Echocardiography  
- Late Gadolinium Enhancement (LGE)  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter-Defibrillator (ICD) therapy  
- Left Ventricular Hypertrophy (LVH)  
- Systolic dysfunction  
- Systolic Anterior Motion (SAM)  
- Subvalvular apparatus  
- Papillary muscles (abnormal positioning, insertion)  
- Accessory muscle bundles  
- Chordal connections  
- Apical aneurysm  
- Myocardial fibrosis  
- Cardiac Computed Tomography (CT)  
- CT angiography  
- Coronary anatomy  
- Coronary stenosis  
- Anomalous origin of coronary arteries  
- Radiation exposure (CT)  
- Heart rhythm assessment  
- 12‑lead Electrocardiogram (ECG)  
- Ambulatory ECG monitoring (24–48 h)  
- Extended (>24 h) ECG monitoring  
- Event recording (for palpitations/light‑headedness)  
- Atrial fibrillation (AF)  
- Anticoagulation  
- Risk score for AF  
- First‑degree relatives (screening)  
- Risk factors (e.g., for AF, SCD)  
- Periodic longitudinal evaluation (CMR)  
- LV wall‑thickness measurement  
- Subaortic membrane  
- Intracardiac thrombus  

Page 19 Extracted Terms:
- 12‑lead ECG  
- LVH (left ventricular hypertrophy)  
- Repolarization changes  
- Wolff‑Parkinson‑White pattern  
- Phenocopies of hypertrophic cardiomyopathy (HCM)  
- Amyloidosis  
- Low‑voltage ECG findings  
- Conduction delays  
- Pseudo‑myocardial‑infarction pattern  
- HCM screening (family screening)  
- Pre‑participation athletic screening  
- Ambulatory electrocardiographic monitoring  
- Ventricular tachyarrhythmias  
- Non‑sustained ventricular tachycardia (NSVT)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Arrhythmias (general)  
- Atrial fibrillation (AF)  
- Stroke (as an AF complication)  
- Left atrial dilatation  
- NYHA functional class III–IV heart failure  
- HCM‑AF risk score  
- Angiography (coronary)  
- Coronary atherosclerosis  
- Surgical myectomy  
- Invasive hemodynamic assessment (cardiac catheterization)  
- LVOTO (left ventricular outflow tract obstruction)  
- Myocardial ischemia  
- Gene carriers (HCM genetics)  
- Echocardiography (screening modality)

Page 20 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Echocardiography (transthoracic echocardiography, TTE)  
- Left‑ventricular outflow tract obstruction (LVOTO)  
- LVOT gradient / LVOT peak gradient  
- Invasive hemodynamic assessment  
- Coronary artery disease (CAD)  
- Coronary angiography  
- Atherosclerosis / atherosclerotic risk factors  
- Myocardial bridging  
- Alcohol septal ablation  
- Exercise stress testing / exercise TTE  
- Cardiopulmonary exercise testing  
- Heart failure (HF)  
- New York Heart Association (NYHA) functional classes II–IV, III–IV, IV  
- Valsalva maneuver  
- Premature ventricular contraction (PVC)  
- Brockenbrough‑Braunwald‑Morrow sign  
- End‑hole pigtail catheter  
- Halo catheter  
- Left‑ventricular function / cardiac output  
- Filling pressures (e.g., left‑systolic filling pressure)  
- Pulmonary hypertension  
- Concomitant valve disease  
- Mechanical circulatory support (e.g., LVAD)  
- Heart transplantation  
- LVOT peak gradient ≥ 50 mm Hg  
- Dynamic LVOTO detection and quantification  
- Provocative maneuvers for LVOT gradient assessment  
- Epicardial CAD assessment  
- Non‑invasive testing (nuclear imaging, stress echo)  
- Exercise TTE for functional capacity and prognostic information  

Page 21 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Heart failure (HF)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Cardiopulmonary exercise test (CPET)  
- Cardiovascular exercise capacity  
- Myocardial ischemia  
- Resting electrocardiogram (ECG)  
- Wall motion abnormalities  
- Myocardial perfusion imaging  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Epicardial coronary artery disease (CAD)  
- Coronary angiography (CT or invasive)  
- Dobutamine stress testing  
- Intracavitary gradients  
- Left ventricular outflow tract (LVOT) obstruction (LVOTO)  
- LVOT gradients  
- Transthoracic echocardiography (TTE)  
- Valsalva maneuver  
- Stress echocardiography  
- Postprandial exercise stress testing  
- Pediatric exercise testing (≥ 7–8 years old)  
- Cardiac transplantation evaluation  
- Abnormal blood pressure response to exercise  
- Transplant‑free survival  
- Exercise‑induced ischemic electrocardiographic changes  
- Chronotropic incompetence  
- Heart rate reserve  
- Peak oxygen consumption (peak VO₂)  
- Peak VO₂ pre‑operative  
- Peak VO₂ post‑operative  
- Ventilatory efficiency  
- Anaerobic threshold  
- Advanced heart failure progression  
- Septal myectomy  
- Functional limitation (provocable LVOTO, abnormal BP response, arrhythmias, etc.)  
- Functional capacity (age‑ and sex‑adjusted)  
- Advanced therapies for LVOTO  
- 3‑generation family history screening  
- Genetic testing for HCM and HCM phenocopies  
- Cascade genetic testing for family members  
- Genetic counseling in cardiovascular disease.

Page 22 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Genetic testing  
- Cascade genetic testing  
- Sudden unexplained death (SCD)  
- Electrocardiogram (ECG)  
- Two‑dimensional echocardiogram  
- Postmortem genetic testing  
- Variant reclassification  
- Variant of uncertain significance (VUS)  
- Genotype‑positive / genotype‑negative  
- Sarcomere genes  
- MYH7  
- MYBPC3  
- TNNI3  
- TNNT2  
- TPM1  
- MYL2  
- MYL3  
- ACTC1  
- PRKAG2 (glycogen‑storage disease)  
- LAMP2 (Danon disease)  
- GLA (Fabry disease)  
- Transthyretin amyloid cardiomyopathy  
- RASopathies  
- Enzyme replacement therapy  
- Pretest genetic counseling  
- Posttest genetic counseling  

These terms encapsulate the major heart‑disease concepts discussed in the guideline excerpt.

Page 23 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Sarcomere variant  
- Pathogenic variant  
- Likely pathogenic variant  
- Variant of Uncertain Significance (VUS)  
- Cascade genetic testing  
- Penetrance  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Atrial Fibrillation (AF)  
- Ventricular arrhythmias  
- Heart Failure (HF)  
- Genetic testing (including exome sequencing, targeted gene panel)  
- Postmortem testing / Molecular autopsy  
- Family screening / clinical surveillance  
- Autosomal dominant inheritance  
- Prenatal genetic counseling  
- In vitro fertilization with preimplantation genetic diagnosis (PGD)  
- Phenotypic heterogeneity

These terms capture the core disease concepts, genetic considerations, diagnostic methods, and clinical interventions discussed in the guideline excerpt.

Page 24 Extracted Terms:
- **Hypertrophic Cardiomyopathy (HCM)**  
- **Atrial Fibrillation (AF)**  
- **Cardiovascular Magnetic Resonance (CMR)**  
- **Cardiopulmonary Exercise Test (CPET)**  
- **Electrocardiography / Electrocardiogram (ECG)**  
- **Echocardiography / Echocardiogram (Echo)**  
- **Heart Failure (HF)**  
- **Implantable Cardioverter‑Defibrillator (ICD)**  
- **Left Ventricular Outflow Tract Obstruction (LVOTO)**  
- **Sudden Cardiac Death (SCD)**  
- **Variant of Unknown Significance (VUS)**  
- **Clinical Screening / Surveillance**

Page 25 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Genotype‑positive, phenotype‑negative individuals  
- Preclinical HCM  
- Left ventricular hypertrophy (LVH)  
- Myocardial strain abnormalities  
- Left ventricular relaxation abnormalities  
- Myocardial crypts  
- Mitral valve leaflet abnormalities  
- Abnormal trabeculae  
- Myocardial scarring  
- Electrocardiographic (ECG) abnormalities  
- Serum NT‑proBNP concentrations  
- Implantable cardioverter‑defibrillator (ICD)  
- Primary prevention  
- Cardiac imaging  
- Serial clinical assessment  
- Electrocardiography  
- Cardiac surveillance  
- Competitive sports participation  
- Pathogenic variant  
- Likely pathogenic variant  
- Variant of unknown significance (VUS)

Page 26 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic cardiomyopathy (HCM)  
- Genotype‑positive, phenotype‑negative individuals  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Medical therapy (e.g., diltiazem)  
- Surgical therapy  
- Device therapy  
- Clinical HCM onset  
- Phenotype conversion  
- Screening (genotype‑positive family members)  
- Age‑related risk (≤18 years, >18 years, mid‑life ≈ 50 years)  
- Family history of SCD  
- Competitive sports participation  
- Ambulatory electrocardiography (AECG)  
- Exercise stress testing  
- Non‑invasive SCD risk assessment  
- Personal history of cardiac arrest or sustained ventricular arrhythmias  
- Personal history of arrhythmic syncope  
- Family history of premature HCM‑related sudden death, cardiac arrest, or sustained ventricular arrhythmias  
- Maximal left ventricular (LV) wall thickness  
- Left ventricular ejection fraction (EF)  
- LV apical aneurysm  
- Nonsustained ventricular tachycardia (NSVT) episodes  
- Cardiac magnetic resonance (CMR) imaging  
- Late gadolinium enhancement (LGE)  
- Echocardiographic parameters: left atrial diameter, LV outflow tract (LVOT) gradient  
- Estimated 5‑year sudden death risk  
- Risk stratification for ICD placement  
- Shared decision‑making  
- SCD risk markers (clinical, imaging, electrophysiologic)  
- Disease penetrance  
- Age‑specific risk prediction models  
- Clinical screening intervals (1–2 years)  

These terms capture the central concepts, risk factors, diagnostic tools, treatment options, and patient management strategies discussed in the guideline excerpt.

Page 27 Extracted Terms:
**Key Heart‑Disease Terms (from the HCM guideline excerpt)**  

- Hypertrophic Cardiomyopathy (HCM)  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Ventricular tachyarrhythmias  
- Nonsustained Ventricular Tachycardia (NSVT)  
- Ventricular Tachycardia (VT)  
- Left Ventricular (LV) wall thickness  
- Left Ventricular Hypertrophy (LVH)  
- Left Ventricular ejection fraction (EF)  
- Late Gadolinium Enhancement (LGE)  
- Cardiovascular Magnetic Resonance (CMR) imaging  
- LV apical aneurysm  
- LV systolic dysfunction (EF < 50 %)  
- Family history of sudden death from HCM  
- Syncope (unexplained, arrhythmia‑related)  
- Genetic testing / genotype status (pathogenic/likely pathogenic variants)  
- Predictive risk scores (5‑year SCD risk)  
- Risk stratification (for ICD decision‐making)  
- Ambulatory electrocardiographic monitoring (24‑48 h)  
- Cardiac imaging (for maximal LV thickness, wall thickness, EF, LGE)  
- Transmural scar (identified by LGE)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Periodic reassessment of SCD risk  
- Longitudinal evaluation of HCM patients  
- Myocardial replacement fibrosis  
- Extensive LGE (≥ 15 % LV mass)  
- Pediatric HCM risk indicators (e.g., maximal wall thickness z‑score ≥ 20, age ≤ 50 yr for family history)

Page 28 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Sudden Cardiac Death (SCD)  
- Estimated 5‑year SCD risk  
- Echocardiographic left atrial diameter  
- Maximal instantaneous LVOT gradient  
- Continuous‑wave Doppler technique  
- Systolic dysfunction (EF < 50%)  
- Ejection fraction (EF)  
- Apical aneurysm  
- Late Gadolinium Enhancement (LGE)  
- Left ventricular (LV) wall thickness  
- Left ventricular outflow tract (LVOT)  
- LV posterior wall thickness  
- Non‑sustained ventricular tachycardia (NSVT)  
- Ambulatory electrocardiographic monitoring  
- Non‑invasive SCD risk assessment  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac magnetic resonance (CMR) imaging  
- Myocardial fibrosis  
- Myocardial replacement fibrosis  
- Genotype / genetic variants  
- Syncope  
- Family history of premature HCM‑related sudden death  
- Personal history of cardiac arrest or sustained ventricular arrhythmias  
- Body surface area–adjusted z‑score for LV wall thickness  
- Risk prediction models for children with HCM  
- Shared decision‑making for ICD placement  
- Psychological impact of ICD implantation  
- Inappropriate ICD shock  
- Contrast‑enhanced CMR  
- 24‑ to 48‑hour monitoring  
- 5‑year risk estimate calculation  
- Interventricular septal thickness in diastole  
- LV wall thickness measurement in any segment  
- Presence of apical aneurysm on imaging  
- Extent of late gadolinium enhancement (LGE) on CMR  
- Pediatric‑specific risk markers  
- Clinical evaluation of risk factors (Figures 1, 3; Table 8)

Page 29 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Sudden Cardiac Death (SCD)  
- Left Ventricular Outflow Tract (LVOT) gradient  
- Non‑Sustained Ventricular Tachycardia (NSVT)  
- Late Gadolinium Enhancement (LGE)  
- Left Ventricular Hypertrophy (LVH)  
- Apical aneurysm (LV apical aneurysm)  
- Left Ventricular ejection fraction (EF)  
- Systolic dysfunction (EF < 50 %)  
- Transmural scar  
- Massive LVH (≥ 30 mm in any LV segment)  
- Unexplained syncope  
- Exercise‑induced ischemia  
- Family history of early HCM‑related SCD  
- Cardiac arrest (documented)  
- Sustained ventricular tachycardia (VT)  
- Ventricular tachyarrhythmias (VT/VF)  
- Contrast‑enhanced Cardiac Magnetic Resonance (CMR) imaging  
- Ambulatory monitoring (for NSVT)  
- Competitive athletics (as a clinical consideration)  
- Risk stratification  
- Shared decision‑making (in ICD placement)  
- Risk‑estimate calculator (5‑year SCD risk)  
- SCD risk markers (e.g., LV apical aneurysm, LGE, EF < 50 %)  

These terms capture the main clinical entities, diagnostic measures, risk factors, and therapeutic considerations discussed in the guideline.

Page 30 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Late gadolinium enhancement (LGE)  
- Left ventricular systolic dysfunction (EF < 50 %)  
- Left ventricular apical aneurysm  
- Risk stratification  
- Risk‑factor algorithm  
- Primary‑prevention ICD  
- Secondary‑prevention ICD  
- Pediatric HCM  
- Age‑appropriate risk factors  
- Genotype status  
- Left atrial diameter z‑score  
- Ambulatory (Holter) monitoring  
- SCD risk calculator  
- Shared‑decision making  
- Long‑term complications of ICD therapy

Page 31 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Transvenous ICD  
- Subcutaneous ICD  
- Single‑chamber ICD  
- Dual‑chamber ICD  
- Single‑coil ICD leads  
- Dual‑coil ICD leads  
- Defibrillation threshold  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Atrial tachycardia  
- Atrial fibrillation (AF)  
- Obstructive HCM  
- Non‑obstructive HCM  
- Cardiac resynchronization therapy (CRT)  
- Left bundle branch block (LBBB)  
- Left ventricular ejection fraction (LVEF)  
- New York Heart Association (NYHA) class  
- Nonsustained ventricular tachycardia (NSVT)  
- Sudden cardiac death (SCD)  
- Late gadolinium enhancement (LGE)  
- Left ventricular hypertrophy (LVH)  
- Bradycardia  
- Conduction abnormalities  
- Pediatric ICD implantation  
- Epicardial leads  
- Family history of HCM  
- Massive LVH  
- Unexplained syncope  
- Cardiovascular magnetic resonance (CMR)  
- Shared decision‑making (as a key process in risk assessment)

Page 32 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Implantable cardioverter‑defibrillator (ICD)  
- Transvenous ICD  
- Subcutaneous ICD  
- ICD lead failure / lead infection  
- Oversensing (post‑exercise)  
- Inappropriate shock  
- Bradycardia pacing  
- Ventricular tachycardia (VT)  
- Defibrillation threshold / testing  
- Single‑coil ICD lead  
- Dual‑coil ICD lead  
- Left‑sided ICD implant  
- Right‑sided ICD implant  
- Epicardial ICD system  
- Left ventricular outflow tract (LVOT)  
- LVOT gradient (≥30 mm Hg)  
- Dual‑chamber pacing system  
- RV apical pacing  
- Cardiac resynchronization therapy (CRT)  
- CRT‑defibrillator  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- New York Heart Association (NYHA) functional class  
- Left ventricular ejection fraction (LVEF)  
- QRS duration  
- Left bundle branch block (LBBB)  
- Beta blockers (non‑vasodilating)  
- LVOT obstruction (LVOTO)  
- Pharmacologic management of obstructive HCM  
- AHA/ACC/HFSA guideline  
- AHA/ACC/HRS guideline  
- Atrial lead  
- Supraventricular arrhythmia  
- Ventricular arrhythmia  
- Pediatric atrial tachyarrhythmia  

These are the principal heart‑disease related terms extracted from the guideline text.

Page 33 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive HCM  
- Left ventricular outflow tract obstruction (LVOTO)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers  
- Verapamil  
- Diltiazem  
- Myosin inhibitor  
- Mavacamten  
- Disopyramide  
- Septal reduction therapy (SRT)  
- Phenylephrine  
- Vasoconstrictors (non‑inotropic)  
- Fluid administration  
- Diuretics  
- Low‑dose oral diuretics  
- High‑dose diuretics  
- Left‑sided filling pressures  
- Volume overload  
- Dyspnea  
- Hypotension  
- Acute hypotension  
- Angiotensin‑converting enzyme inhibitors (ACE inhibitors)  
- Angiotensin receptor blockers (ARBs)  
- Dihydropyridine calcium channel blockers  
- Digoxin  
- Left ventricular ejection fraction (LVEF)  
- Outflow tract gradient  
- Dynamic LV obstruction  
- Pharmacologic therapy  
- Symptom relief  
- Risk evaluation and mitigation strategy  
- Comprehensive HCM centers  
- Midventricular obstruction

Page 34 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- LVOT gradient  
- Septal Reduction Therapy (SRT)  
- Alcohol Septal Ablation  
- Surgical Myectomy  
- Mitral Valve Replacement  
- Atrioventricular Node  
- Atrial Fibrillation (AF)  
- β‑Blocker  
- Verapamil  
- Diltiazem  
- Disopyramide  
- Phenylephrine (intravenous vasoconstrictor)  
- Diuretics  
- Vasoconstrictors  
- Vasodilators  
- Inotropic agents  
- Guideline‑Directed Medical Therapy (GDMT)  
- New‑Guideline Recommendations (NG)  
- Acute Hypotension  
- Preload  
- Afterload  
- Contractility  
- Heart Rate  
- Supraventricular Tachycardia  
- Congestive Heart Failure (HF)  
- Pulmonary Hypertension  
- Left Atrial Enlargement (LAE)  
- Systolic Anterior Motion (SAM)  
- Anomalous Papillary Muscle  
- Elongated Anterior Mitral Leaflet  
- Intrinsic Mitral Valve Disease  
- Multivessel Coronary Artery Disease (CAD)  
- Aortic Stenosis  
- NYHA Functional Class  
- Dynamic LVOT Gradient at Rest or Provocation  
- Targeted Anterior Septal Thickness  
- Comprehensive HCM Centers  
- Symptom‑relief of LVOTO  
- Hemodynamic Parameters (gradient ≥ 50 mm Hg)  
- Clinical Eligibility Criteria  
- Early Surgical Intervention (NYHA II)  
- Risk Stratification (Serious Comorbidities, Advanced Age)  
- Shared Decision‑Making in Treatment Choices  
- Contraindication: High‑Dose Diuretics  
- Contraindication: Pure Vasodilators  
- Contraindication: Positive Inotropes  
- Conduction System Modulation  
- Pre‑operative Functional Capacity Assessment  
- Treadmill Exercise Testing  
- SRT Not Recommended in Asymptomatic Patients  
- Mitral Regurgitation (MR) Associated with LVOTO  
- SRT in Pediatric and Young Adult Patients (> 100 mm Hg gradient)  
- Use of β‑Blockade with Vasoconstrictor to Reduce Heart Rate and Contractility  
- Low‑Dose Diuretics for Congestion in HCM  
- Aggressive Diuresis Leading to LVOTO Amplification  
- High-Grade LVOT Gradients (80–100 mm Hg)  
- Life‑threatening Bradycardia with Verapamil in Neonates  
- Clinical Outcomes for SRT and Surgical Myectomy  
- Safety Profile of Verapamil and Diltiazem in HCM  
- Post-Treatment Surveillance of LVOT Gradients  
- Role of Primary HCM Centers in Procedural Excellence  
- Management of Concomitant Cardiac Conditions in HCM  
- Use of Vasodilators in Hypertension and Renal Protection  
- Treatment of Concomitant Coronary Artery Disease in HCM patients  
- Pharmacologic Modulation of Preload and Afterload in HCM Therapy.

Page 35 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Septal Myectomy (surgical)  
- Transaortic Septal Myectomy / Extended Septal Myectomy (ESM)  
- Alcohol Septal Ablation  
- Septal Reduction Therapy (SRT)  
- Atrial Fibrillation (AF) / Paroxysmal AF  
- Pulmonary Vein Isolation  
- Maze Procedure  
- Anomalous Papillary Muscle  
- Elongated Anterior Mitral Leaflet  
- Mitral Regurgitation (MR)  
- Coronary Artery Disease (CAD)  
- Aortic Stenosis  
- Left Ventricular Hypertrophy  
- Pulmonary Hypertension  
- Left Atrial Enlargement  
- Arrhythmia (atrial, ventricular)  
- Permanent Pacemaker  
- New‑Onset AF Burden  
- NYHA Functional Class  
- HCM Center / Comprehensive Center  
- Modified Konno Procedure  
- Transapical Approach  
- Combined Transaortic & Transapical Approach  
- Gradient Relief (LVOT gradient)  
- Post‑operative Hemodynamic Instability  
- Recurrent Outflow Tract Obstruction  
- Systolic Anterior Motion (SAM)  
- Clinical Success Rate  
- Operative Mortality Rate  
- Pacemaker Implantation Risk  
- Repeat Intervention Risk  
- Surgical Myectomy Benefit (e.g., improvement in pulmonary hypertension, exercise tolerance, reverse atrial enlargement)

Page 36 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Nonobstructive HCM  
- Obstructive HCM  
- Septal myectomy  
- Septal reduction therapy (SRT)  
- Systolic anterior motion (SAM)  
- Mitral regurgitation (MR)  
- Mitral valve replacement  
- Mitral valve repair  
- NYHA functional class  
- Angina  
- Dyspnea  
- Heart failure (HF)  
- Left ventricular (LV) dysfunction  
- LV wall thickness  
- LV end‑diastolic volume  
- LV stroke volume  
- Diastolic dysfunction  
- Restrictive physiology  
- Coronary artery disease (CAD)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)  
- Oral diuretics  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Valsartan  
- Procedural mortality  
- Hospital morbidity/mortality  
- Length of hospitalization  
- Shared decision‑making  
- Exercise tolerance  
- Ventricular remodeling  
- Pathogenic cardiac sarcomere genetic variant  
- Implantable cardioverter‑defibrillator (ICD)  
- Hypertension  
- Diabetes  
- Obesity  
- Obstructive sleep apnea  
- Physical inactivity

Page 37 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive HCM  
- Non‑obstructive HCM  
- LV outflow tract obstruction (LVOTO)  
- Left ventricular ejection fraction (LVEF)  
- Systolic dysfunction  
- Diastolic dysfunction  
- LV mass  
- LV wall thickness  
- LV end‑diastolic volume  
- LV stroke volume  
- LV end‑diastolic pressure  
- Left atrial size  
- Diastolic parameters  
- Left ventricle (LV)  
- Myocardial fibrosis  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- NYHA functional class I–IV  
- NYHA class III–IV  
- Guideline‑directed medical therapy (GDMT)  
- Beta blockers  
- Nondihydropyridine calcium‑channel blockers  
- Verapamil  
- Diltiazem  
- Loop diuretics  
- Thiazide diuretics  
- Aldosterone antagonists  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Losartan  
- Valsartan  
- Sarcomeric genetic variants  
- Angina  
- Refractory angina  
- Dyspnea  
- Ventricular arrhythmias  
- Transapical myectomy  
- Heart transplantation  
- Mechanical circulatory support  
- Cardiopulmonary exercise testing (CPET)  
- Implantable cardioverter‑defibrillator (ICD)  
- ICD shocks (appropriate ICD shocks)  
- Chronotropic incompetence  
- Ambulatory ECG  
- Stress test (exercise test)  
- Bradycardia  
- Atrioventricular conduction block  
- LV end‑diastolic volume <50 mL/m² (small cavity definition)  
- LV stroke volume <30 mL/m² (small cavity definition)

Page 38 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Heart Failure (HF)  
- Nonobstructive HCM  
- Obstructive HCM / LVOTO (left ventricular outflow tract obstruction)  
- New York Heart Association (NYHA) functional classes I–IV  
- Left Ventricular Ejection Fraction (LVEF)  
- Reduced LVEF (<50%)  
- Severely reduced LVEF (<35%)  
- Generalized Disease‑Managing Therapy (GDMT)  
- Cardiac resynchronization therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Left Ventricular Assist Device (LVAD)  
- Continuous‑flow LVAD  
- Heart transplantation / transplant evaluation  
- Life‑threatening ventricular arrhythmias  
- Sudden Cardiac Death (SCD)  
- Ventricular tachycardia/fibrillation (VT/VF)  
- Ventricular arrhythmia monitoring  
- Cardiopulmonary exercise testing (CPET)  
- Peak oxygen consumption (VO₂ peak)  
- Minute ventilation to CO₂ production (VE/VCO₂)  
- Ventilatory anaerobic threshold  
- Cardiac myosin inhibitors (e.g., mavacamten)  
- Negative inotropes (verapamil, diltiazem, disopyramide)  
- Restrictive physiology / restrictive cardiomyopathy phenotype  
- Left Ventricular (LV) dilation / chamber size  
- Coronary Artery Disease (CAD)  
- Valvular heart disease  
- Metabolic disorders affecting the heart  
- AHA/ACC/HFSA heart failure guideline  
- United Network for Organ Sharing (UNOS) heart transplant allocation policy  
- Heart transplant listing criteria for HCM  
- Mechanical circulatory support (MCS)  
- Advanced heart failure therapies  
- Clinical guideline classification (e.g., B‑NR, B‑R, C‑EO, C‑LD)  
- Prognostic risk stratification tools  

These terms capture the key concepts, diagnoses, therapeutic interventions, risk factors, diagnostic tools, and guideline references relevant to heart disease as discussed in the provided text.

Page 39 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Cardiomyopathy  
- Myocardial contractility  
- Left Ventricular Ejection Fraction (LVEF)  
- Mavacamten (myosin‑inhibitor drug)  
- Heart transplantation  
- Management of symptoms in HCM  
- Clinical guideline (2024 Hypertrophic Cardiomyopathy Guideline)

Page 40 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Heart failure algorithm  
- Cardiac myosin inhibitor  
- Left ventricular ejection fraction (LVEF) / ejection fraction (EF)  
- Cardiac resynchronization therapy (CRT)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular assist device (LVAD)  
- Left bundle branch block (LBBB)  
- New York Heart Association (NYHA) classification  

Page 41 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular ejection fraction (LVEF)  
- Systolic dysfunction  
- Heart failure (HF)  
- LVAD (left ventricular assist device)  
- ICD (implantable cardioverter‑defibrillator)  
- Cardiac resynchronization therapy (CRT)  
- Atrial fibrillation (AF)  
- Direct‑acting oral anticoagulants (DOACs)  
- Vitamin K antagonists (e.g., warfarin)  
- Beta‑blockers  
- Verapamil  
- Diltiazem  
- Disopyramide  
- Temporary mechanical circulatory support (e.g., biventricular support)  
- Ventricular arrhythmias / malignant arrhythmias  
- LV cavity size / dimensions (e.g., ≥46‑50 mm)  
- QRS duration (≥150 ms)  
- Left bundle branch block (LBBB)  
- Malignant arrhythmia risk stratification (SHaRe score)  
- Sudden cardiac death (SCD)  
- AF burden / episode duration (>24 h or >5 min)  
- Cardioversion and rhythm‑control strategies  
- Catheter ablation for AF  
- Surgical myectomy with concomitant AF ablation  
- HF hospitalizations  
- Survival outcomes in HF/HCM patients  
- Anticoagulation strategy independent of CHA₂DS₂‑VASc score  
- Systolic EF thresholds (≤35%, 35‑50%, ≤50%)  

These terms capture the major heart‑disease concepts referenced in the guideline excerpts.

Page 42 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Clinically evident AF  
- Asymptomatic/Subclinical AF (SCAF)  
- Atrial flutter  
- Thromboembolic events / thromboembolism  
- Stroke risk / systemic embolization  
- Anticoagulation therapy  
- Vitamin K antagonists (e.g., warfarin)  
- Direct oral anticoagulants (DOACs)  
- Left atrial appendage occlusion devices  
- CHA₂DS₂‑VASc score  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Antiarrhythmic drugs  
- Catheter ablation  
- Surgical atrial fibrillation ablation  
- Myectomy (surgical myectomy)  
- Supraventricular arrhythmias  
- Cardiac devices / implantable devices  
- Device‑detected AF  
- Intracardiac electrocardiograms (ECGs)  
- Cardiac imaging for monitoring AF burden  
- Left ventricular outflow tract obstruction (LVOTO)  
- Nondihydropyridine calcium channel blockers  
- Beta‑blockers  
- Digoxin  
- Verapamil  
- Atrioventricular node ablation  
- Pacemaker implantation  
- Stroke prevention measures  
- Antithrombotic therapy effectiveness  
- AF duration thresholds  
- AF burden metrics  
- Thromboembolism incidence in HCM  
- Anticoagulation risk-benefit assessment in HCM.

Page 43 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Stroke  
- CHADS2 score  
- NYHA functional class  
- Left atrial diameter  
- Vascular disease  
- Left ventricular (LV) wall thickness  
- LV outflow tract obstruction (LVOTO)  
- Diastolic dysfunction / impairment  
- Mitral regurgitation (MR)  
- Antiarrhythmic drugs  
  - Amiodarone  
  - Disopyramide  
  - Flecainide  
  - Propafenone  
  - Sotalol  
  - Dofetilide  
  - Dronedarone  
- Implantable cardioverter‑defibrillator (ICD)  
- Catheter ablation  
- Electrophysiologic remodeling  
- Structural remodeling  
- Atrial remodeling  
- Torsades de pointes (TdP)  
- Prolonged QTc  
- Proarrhythmia  
- Bradycardia  
- Fatigue  
- Headache  
- Hepatic toxicity (liver)  
- Pulmonary toxicity (lung)  
- Endocrine toxicity (thyroid)  
- Dermatologic toxicity (skin)  
- Neurologic toxicity (neurologic)

Page 44 Extracted Terms:
Hypertrophic Cardiomyopathy (HCM)  
HCM  
Atrial fibrillation (AF)  
AF  
Catheter ablation  
Surgical AF ablation  
Open heart surgery  
Myectomy  
Left ventricular outflow tract (LVOT) gradient  
LVOT gradient  
Mitral regurgitation (MR)  
MR  
Negative atrial remodeling  
Atrial remodeling  
Ventricular arrhythmias  
Ventricular tachyarrhythmias  
Life‑threatening ventricular tachyarrhythmia  
Heart transplantation  
Transplant assessment  
Implantable cardioverter‑defibrillator (ICD)  
ICD  
Antiarrhythmic drug therapy  
Amiodarone  
Dofetilide  
Mexiletine  
Sotalol  
Beta‑blockers  
Propafenone  
Flecainide  
Antitachycardia pacing  
Programming antitachycardia pacing  
Sustained monomorphic VT  
Ventricular flutter  
ICD shocks  
ICD programming  
Arrhythmia burden  
Left atrial size  
AF recurrence  
AF burden  
Quality of life  
Overall survival  
Transplant referral  
OPTIC trial (Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients)  
Heart failure (HF)  
Advanced heart failure  
Restrictive physiology  
Intracardiac arrhythmias

Page 45 Extracted Terms:
**Key terms related to heart disease (as extracted from the provided text)**

- Hypertrophic cardiomyopathy (HCM)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Ventricular flutter  
- Anti‑arrhythmic agents / therapy  
- Anti‑tachycardia pacing (ATP)  
- Catheter ablation  
- Epicardial ablation  
- Endocardial ablation  
- Combined epicardial‑endocardial ablation  
- Apical aneurysm  
- Aneurysmectomy (surgical aneurysmectomy)  
- Sympathetic denervation  
- Left cardiac sympathetic denervation (LCS)  
- Proarrhythmia (drug‑induced arrhythmia)  
- ICD shocks (appropriate and inappropriate)  
- Recurrent ventricular arrhythmias  
- Pharmacologic therapy (beta‑blockers, etc.)  
- Psychological trauma related to ICD shocks  
- Cardiorespiratory fitness  
- Physical performance / endurance  
- Recreational physical activity (moderate–vigorous intensity)  
- Competitive sports participation  
- Metabolic equivalents (METs) – light, moderate, vigorous  
- Borg scale of perceived exertion  
- Phenotype‑negative / genotype‑positive status for HCM  
- Shared decision‑making (SDM) in sports/physical activity  
- Comprehensive cardiac evaluation (annual reassessment)  
- ICD placement for sports participation (contraindicated)  
- Cardiac risk stratification for HCM patients  

These terms capture the principal clinical concepts, interventions, and lifestyle considerations pertaining to heart disease as described in the guideline excerpt.

Page 46 Extracted Terms:
- Hypertrophic cardiomyopathy  
- HCM  
- Sudden cardiac death (SCD)  
- Genotype‑positive, phenotype‑negative status  
- Ventricular arrhythmias  
- Arrhythmic events  
- Exercise intensity  
- METs (metabolic equivalents)  
- Moderate‑intensity exercise  
- Vigorous‑intensity exercise  
- Peak oxygen consumption  
- Nonlethal arrhythmias  
- Risk prediction models for SCD  
- Family history of SCD  
- NYHA functional class I‑II  
- Cardiovascular mortality  
- Obstructive physiology  
- Ambulatory electrocardiography  
- Exercise stress testing  
- Physical activity guidelines for adults and children  
- Aerobic exercise  
- Competitive sports participation  
- Exercise training compliance  
- Electrocardiographic monitoring (ECG)

Page 47 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Sudden Cardiac Death (SCD)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Ventricular arrhythmias  
- Competitive athletics / sports participation  
- Arrhythmic events  
- Arrhythmic risk  
- ICD shock rates  
- ICD utilization  
- Risk stratification for SCD  
- SCD risk assessment  
- Low‑molecular‑weight heparin (anticoagulation)  
- Vitamin K antagonists (anticoagulation)  
- Federal Motor Carrier Safety Administration (FMCSA) guidelines  
- Federal Aviation Administration (FAA) guidelines  
- Clinical evaluation of occupational risk  
- Shared decision‑making  
- Commercial driving (occupational consideration)  
- Piloting an aircraft (occupational consideration)  
- Manual labor / heavy lifting occupational consideration  
- High physical performance occupations (law enforcement, firefighters)  

Page 48 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Beta‑blockers (e.g., metoprolol, bisoprolol, labetalol, pindolol, propranolol, atenolol)  
- Arrhythmias (atrial fibrillation, ventricular arrhythmias)  
- Cardioversion (for new or recurrent AF)  
- General or epidural anesthesia (used during delivery)  
- Echocardiography (serial maternal and fetal imaging)  
- Fetal echocardiography (for diagnosis of fetal HCM)  
- Maternal‑fetal medicine (specialist care coordination)  
- Anticoagulation therapy  
  - Low‑molecular‑weight heparin  
  - Warfarin  
  - Direct oral anticoagulants (DOACs)  
- Stroke risk in HCM patients with AF  
- Maternal mortality in HCM pregnancy (very low)  
- Heart failure (HF) in the context of HCM  
- Mavacamten (contraindicated in pregnancy)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Surgical relief therapy (SRT) for refractory LVOTO  
- Advanced heart failure therapies (considered pre‑conception)  
- Valsalva maneuver (during labor)  
- Vaginal delivery (preferred first‑choice delivery option)  
- Cesarean section (reserved for obstetric or emergency cardiac indications)  
- Pregnancy counseling  
  - Preconceptional genetic counseling  
  - Prenatal genetic counseling  
  - Preimplantation genetic testing  
  - Fetal screening  
  - Postnatal genetic testing  
- Maternal/fetal risk assessment  
- Reproductive options (informed decision‑making)

Page 49 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Left Ventricular Hypertrophy (LVH)  
- Heart Failure (HF)  
- Atrial Fibrillation (AF)  
- Ventricular Arrhythmias  
- Stroke  
- Beta‑blockers  
- Non‑dihydropyridine Calcium Channel Blockers  
- Diuretics  
- Vasodilators  
- Anticoagulation  
- Thromboembolism  
- Cardioversion  
- Sleep‑Disordered Breathing  
- Obesity  
- Hypertension  
- Primary Prevention  
- Myosin Inhibitors  
- Fetal Echocardiography  
- Echocardiography  
- Pregnancy (obstetric considerations for HCM)  
- Anesthesia (epidural, general)  
- Gene Variant Carriers  
- Sarcomere Gene Variant.

Page 50 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Non‑obstructive HCM  
- Obstructive HCM  
- Sleep‑disordered breathing  
- Obstructive sleep apnea  
- Atrial fibrillation (AF)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Left ventricular (LV) wall thickness  
- Left ventricular hypertrophy (LVH)  
- Diastolic abnormalities  
- Restrictive physiology  
- Myocardial energetics  
- Cardiac myosin inhibitors  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Mineralocorticoid receptor antagonists  
- Heart failure with preserved ejection fraction (HF‑PEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Risk stratification  
- Late gadolinium enhancement (LGE)  
- 3‑dimensional strain (3D strain)  
- Cardiac magnetic resonance (CMR)  
- Troponin  
- Genetic sarcomere variant  
- Hypertension  
- Valsartan  
- Gene‑based therapy  
- Cardiopulmonary rehabilitation  
- Artificial intelligence (risk prediction)  
- Arrhythmia management  
- Thromboembolic complications  
- Ablation therapy  
- Left ventricular function  
- Clinical guidelines  
- Diagnostic criteria  
- Phenotype  
- Pathophysiology  
- Molecular diagnosis  
- Pathogenesis  
- Predictors of disease progression  
- Biomarkers

Page 51 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Cardiac genetics  
- Genetic evaluation  
- Genetic counseling  
- Genetic testing  
- Variant of uncertain significance  
- ClinGen (Clinical Genome Resource)  
- National Institutes of Health (NIH)  
- Polygenic risk scores  
- Genotype‑phenotype correlation  
- Clinical outcomes  
- Family management of heart disease  
- Tailored therapies  
- Gene‑specific therapeutics  
- Cardiomyopathy (general)  
- Heart disease (general)  
- Longitudinal cardiac screening  
- Environmental factors influencing cardiomyopathy  
- Precision medicine in cardiology  
- Screening stratification risk prediction  

Page 52 Extracted Terms:
**Key heart‑disease terms mentioned in the text**

- Hypertrophic Cardiomyopathy  
- Atrial Fibrillation  
- Heart Failure  
- Cardiovascular Disease (and primary prevention)  
- Cardiac Rhythm Abnormalities  
- Device‑Based Therapy of Cardiac Rhythm Abnormalities  

These terms capture the primary disease entities and therapeutic focus areas highlighted in the clinical guideline references.

Page 53 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Ventricular arrhythmias  
- Sudden cardiac death  
- Left ventricular outflow tract obstruction  
- Bradycardia  
- Cardiac conduction delay  
- Coronary artery disease  
- Atherosclerotic vascular disease  
- Valvular heart disease  
- Hypertension  
- Genetic cardiomyopathy  
- Phenotype  
- Genotype  
- Cardiovascular risk factors  
- Atrial fibrillation  
- Ischemic heart disease  
- Heart failure  
- Cardiac catheterization  
- Echocardiography  
- Exercise stress echocardiography  
- Dobutamine stress echocardiography  
- Valsalva maneuver  
- Amyl nitrite  
- Post‑prandial hemodynamics  
- Respiratory‑related fluctuations  
- Dynamic obstruction  
- Genetic pathways  
- Clinical guidelines  
- Clinical practice guidelines  
- AHA/ACC/HRS  
- ACCF/AHA  
- ESC  
- Clinical diagnosis  
- Cardiac risk assessment  
- Secondary prevention  
- Risk reduction therapy  
- Obstructive physiology  
- Intraventricular gradients  
- Takotsubo syndrome  
- Obstructive cardiomyopathy  
- Dynamic intraventricular obstruction  
- Exercise‑induced gradient  
- Obliquely arranged myocytes  
- Genotype‑based burden of disease  
- Cardiovascular mortality  
- Asymptomatic adult cardiac risk assessment  
- Prevention of cardiovascular disease in women  
- Genetic screening for cardiomyopathy  
- Cardiac imaging  
- Multimodal imaging  
- Clinical course of hypertrophic cardiomyopathy  
- Exercise echocardiography  
- Stress‑induced gradient  
- Genetic testing  
- Clinical phenotype in hypertrophic cardiomyopathy  
- Cardiac genetics  
- Cardiovascular surveillance  
- Prognosis of hypertrophic cardiomyopathy  

(Note: Each line represents a distinct heart‑disease‑related term extracted from the source text.)

Page 54 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Diastolic dysfunction  
- Left ventricular (LV) outflow tract obstruction  
- Mitral regurgitation  
- Myocardial ischemia  
- Autonomic dysfunction  
- Ventricular tachycardia  
- Myocardial bridging  
- Epicardial coronary artery disease  
- Small vessel (intramural) coronary disease  
- Myocardial stiffness  
- Echocardiographic strain imaging  
- Cardiac magnetic resonance imaging (CMR)  
- Left ventricular systolic‑diastolic coupling  
- Septal myectomy  
- Alcohol septal ablation  
- Risk stratification for sudden cardiac death  
- Heart rate recovery (post‑exercise)  
- Blood pressure response during exercise  
- Left ventricular hypertrophy (interventricular septum)  
- Left atrial enlargement  
- Valvular heart disease (mitral, aortic)  
- Apical aneurysm  
- Valve surgery (repair/replacement)  
- Catheter ablation (ventricular tachycardia)  
- Shared decision‑making in HCM management  
- Multidisciplinary HCM centers  
- Vascular dilator reserve impairment  
- Coronary perfusion deficit  
- Myocardial energy impairment during exercise  

These terms capture the key cardiovascular disease concepts referenced in the provided clinical guideline excerpts.

Page 55 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular hypertrophy  
- Left ventricular outflow tract obstruction  
- Septal myectomy  
- Mitral valve replacement  
- Valvular heart disease  
- Advanced heart failure  
- Advanced therapies (e.g., surgical, mechanical support)  
- Heart transplant  
- Myocardial fibrosis  
- Cardiac magnetic resonance imaging  
- Doppler echocardiography  
- Transesophageal echocardiography  
- Two‑dimensional echocardiography  
- Three‑dimensional echodoppler imaging  
- Multimodality cardiovascular imaging  
- Systolic impairment  
- Left ventricular remodeling  
- Cardiac genetics  
- Family screening for cardiomyopathy  
- Genetic counseling  
- Sudden cardiac death risk stratification  
- Implantable cardioverter‑defibrillator (ICD)  
- Lethal arrhythmic events  
- Valsalva maneuver (echo provocation)  
- Amyl nitrite provocation  
- Exercise echocardiography  
- Upright treadmill exercise testing  
- Semi‑supine bicycle exercise testing  
- Appropriate use criteria for echocardiography  
- Intraoperative echocardiographic guidance  
- Intraoperative decision making  
- Clinical staging of hypertrophic cardiomyopathy  
- Clinical diagnosis and imaging protocols  
- Cardiac catheterization (pressure measurement)  
- ESC, ACC, AHA, AATS/ACC/ASE/SCAI/STS guidelines and consensus documents  

---

Page 56 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Hypertrophic obstructive cardiomyopathy  
- Apical hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Transluminal septal ablation  
- Alcohol septal ablation  
- Transcoronary ablation of septal hypertrophy (TASH)  
- Intraprocedural myocardial contrast echocardiography  
- Echocardiographic monitoring  
- Cardiovascular magnetic resonance imaging (CMR)  
- Late gadolinium enhancement (LGE)  
- Myocardial strain imaging  
- Tissue Doppler imaging  
- Diastolic dysfunction  
- Myocardial necrosis  
- Septal myectomy  
- Aneurysm (left ventricular apical aneurysm)  
- Mitral valve abnormalities  
- Papillary muscle morphology  
- Left ventricular wall thickness measurement  
- Left ventricular remodeling  
- Genetic counselling  
- Genetic testing  
- Family screening for hypertrophic cardiomyopathy  
- Penetrance of hypertrophic cardiomyopathy  
- Risk stratification of sudden cardiac death  
- Ventricular septal thickness  
- Intraprocedural echocardiography  
- Ultrasound enhancing agents  
- Post‑prandial upright exercise echocardiography  
- Contrast‑enhanced cardiovascular magnetic resonance  
- Subclinical hypertrophic cardiomyopathy  
- Dilated cardiomyopathy (in genetic context)  
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)  

Page 57 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Papillary muscle insertion (antero‑mitral leaflet)  
- Myocardial fibrosis  
- Late gadolinium enhancement  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CT)  
- Electrocardiogram (ECG)  
- Ambulatory ECG monitoring (Holter)  
- Atrial fibrillation (subclinical, device‑detected, silent episodes)  
- Ventricular tachycardia / non‑sustained ventricular tachycardia  
- Sudden cardiac death risk  
- Coronary artery disease / epicardial coronary disease  
- Left ventricular hypertrophy (LVH)  
- Left ventricular filling pressures  
- Isoproterenol challenge  
- Doppler echocardiography (rest, exercise, upright)  
- Valsalva maneuver / amyl nitrite provocation  
- Cardiopulmonary exercise testing (CPET)  
- Cardiac catheterization (direct pressure measurement, left atrial pressure)  
- Surgical myectomy / papillary muscle surgical management  
- Diagnostic predictive models (e.g., HCM‑AF Score)  
- Exercise‑induced LV outflow tract gradient  
- Heart‑rate reserve during exercise  
- Pre‑operative coronary angiography assessment  
- Athlete’s heart differential diagnosis  
- Competitive athlete eligibility/disqualification criteria  
- Heart‑failure progression in HCM  
- Prognostic implications of arrhythmias  
- Outflow tract gradient variability  
- Late/ delayed myocardial enhancement quantification  
- Echocardiographic assessment of obstruction severity  
- Cardiometabolic stress testing (treadmill, semi‑supine bicycle)  

These terms capture the major clinical entities, diagnostic modalities, physiological assessments, and therapeutic contexts discussed in the guideline excerpts.

Page 58 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Left ventricular outflow tract gradient  
- Amyl nitrite provocation  
- Cardiopulmonary exercise test  
- Exercise testing  
- Septal myectomy  
- Surgical myectomy  
- Post‑prandial upright exercise echocardiography  
- Long‑term survival  
- Imaging phenotype  
- Phenotypic expression  
- Cardiac genotype  
- LAMP2 cardiomyopathy  
- Pediatric cardiomyopathy  
- Family screening  
- Cardiovascular genetics  
- Genetic counselling  
- Genetic testing  
- Pathogenic variants  
- Variant pathogenicity  
- Clinically actionable variants  
- Penetrance  
- Sudden cardiac death  
- Cardiomyopathy (general)  
- Clinical outcome  
- Prognostic relevance  
- Risk stratification  
- Clinical validity of genetic tests  
- Variant interpretation  
- Whole genome sequencing  
- Genetic misdiagnosis  
- Health disparities  
- Compound and double mutations  
- Non‑familial hypertrophic cardiomyopathy  
- Disease burden  
- Prevalence  
- Anderson‑Fabry disease (in hypertrophic cardiomyopathy)  
- Molecular autopsy  
- Arrhythmias  
- Psychosocial care for inherited cardiovascular disease  
- Left ventricular hypertrophy  
- Cardiovascular disease  
- Clinical screening  
- Clinical yield  
- Cardiovascular genetics programs  
- Risk of cardiomyopathy with family history  
- Pediatric risk assessment  
- Genetic testing outcomes  
- Clinical screening for hypertrophic cardiomyopathy in first‑degree relatives  
- Genetic counseling and testing guidelines  
- Genetic counseling services  
- Clinical screening paradigms  
- Cardiovascular genetics consensus recommendations  
- Clinical screening strategies  
- Clinical testing in children and adolescents  
- Molecular autopsy for sudden death  
- Cardiovascular screening guidelines  
- Cardio‑respirology exercise diagnostics  
- Cardiovascular phenotyping  
- Clinical predictors of genetic testing outcomes  
- Genetic variant re‑analysis  
- Genetic variant re‑contact guidelines  
- Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy  
- Clinical outcome after septal myectomy  
- Clinical outcome after surgical myectomy  
- Clinical outcome in hypertrophic cardiomyopathy patients  
- Clinical outcome of exercise capacity post‑septal myectomy

Page 59 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular hypertrophy  
- Left ventricular wall thickness  
- Left ventricular outflow obstruction  
- Left ventricular apical aneurysm  
- Apical hypertrophic cardiomyopathy  
- Left ventricular remodeling  
- Ventricular tachycardia  
- Non‑sustained ventricular tachycardia  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator  
- Implantable defibrillator therapy  
- Cardiac magnetic resonance imaging  
- Late gadolinium enhancement  
- Magnetic resonance imaging (MRI)  
- Transthoracic echocardiography  
- Echocardiography  
- Sarcomere mutation  
- Genotype positive  
- Phenotype negative  
- Family history of sudden death  
- Risk stratification  
- Risk prediction model  
- HCM Risk‑SCD model  
- HCM Risk‑Kids model  
- Prognosis  
- Prognostic value  
- Clinical risk prediction  
- Cardiovascular mortality  
- Mortality rates  
- Vigorous exercise  
- Clinical outcomes  
- Left ventricular systolic dysfunction  
- Pediatric hypertrophic cardiomyopathy  
- Adult‑onset hypertrophic cardiomyopathy  
- Ventricular fibrillation (implied)  
- Apical outpouching  
- Left ventricular strain  
- Sarcomere mutation carriers.

Page 60 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular diastolic function  
- Tissue Doppler imaging  
- Clinical status  
- Childhood / pediatric heart disease  
- Adolescents / young adults  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Risk stratification  
- HCM Risk‑Kids model  
- Genetic risk factors  
- Late gadolinium enhancement (LGE)  
- Cardiovascular magnetic resonance (CMR)  
- Echocardiography  
- Left ventricular wall thickness  
- Left ventricular apical aneurysm  
- Massive left ventricular hypertrophy  
- Arrhythmic events  
- Epidemiology of hypertrophic cardiomyopathy  
- Clinical outcomes  
- Prognostic value of CMR  
- Exercise test abnormalities  
- Contemporary management strategies  
- Mortality and survival analysis  
- Clinical features and outcomes, population‑based study  

These are the key heart‑disease–related terms that emerge from the cited clinical guidelines and studies.

Page 61 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Sudden cardiac death (SCD)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular systolic dysfunction (LVSD)  
- Left ventricular remodeling  
- End‑stage hypertrophic cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Syncope  
- Exercise test abnormalities  
- Family history of sudden death  
- Risk stratification  
- Prognostic implications  
- Late gadolinium enhancement (LGE)  
- Cardiovascular magnetic resonance (CMR)  
- Left ventricular apical aneurysm  
- Left ventricular outflow obstruction  
- Preventive ICD therapy  
- Pediatric hypertrophic cardiomyopathy  
- HCM Risk-SCD model  
- HCM Risk‑Kids model  
- Sudden death risk prediction  
- Implantable defibrillator complications  
- Adult HCM management strategies  
- Pediatric HCM management strategies  
- Pediatric arrhythmic events  
- Clinical risk factors  
- Echocardiographic assessment  
- Electrocardiographic identification  
- Contemporary management strategies  
- Long‑term follow‑up outcomes  
- Prognostic determinants  
- Ventricular tachycardia outcomes  

Page 62 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- End‑stage hypertrophic cardiomyopathy  
- Dilated‑phase hypertrophic cardiomyopathy  
- Hypertrophic subaortic stenosis  
- Sudden death risk  
- Sudden cardiac death  
- Left ventricular outflow tract gradients  
- Angina pectoris  
- Late gadolinium enhancement (LGE)  
- LGE‑CMR (late gadolinium‑enhanced cardiovascular magnetic resonance)  
- Implantable cardioverter‑defibrillator (ICD)  
- Subcutaneous ICD (S‑ICD)  
- Dual‑chamber ICD  
- Single‑chamber ICD  
- Defibrillation threshold  
- Dual‑chamber pacing  
- Single‑coil defibrillator lead  
- Cardiac resynchronization therapy (CRT)  
- Biventricular pacing  
- Cardiac remodeling  
- Bradycardia  
- Cardiac conduction delay  
- Tachyarrhythmia detection algorithms  
- Inappropriate ICD shock  
- Beta‑adrenergic blockade (beta‑blockers)

Page 63 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Hypertrophic subaortic stenosis (SAS)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Surgical septal myectomy  
- Alcohol septal ablation (ASA)  
- Verapamil therapy  
- Diltiazem therapy  
- Propranolol therapy  
- Disopyramide therapy  
- Mavacamten (myosin inhibitor)  
- β‑blocker therapy  
- Pulmonary hypertension  
- Mitral valve abnormalities (mitral regurgitation, papillary muscle insertion)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death risk  
- Resting LVOT gradient  
- Exercise echocardiography  
- Left atrial remodeling / enlargement  
- Conduction abnormalities  
- Acquired von Willebrand syndrome  
- Transaortic myectomy  
- Aortic valve replacement (SAVR) with concomitant septal myectomy  
- Hospital volume outcomes  
- Surgical management of LVOT obstruction  
- Constrictive left ventricular hypertrophy  
- Symptom status (NYHA class)  
- Gradient resistant to first‑line therapy  
- Vascular dysfunction (von Willebrand factor activity)  
- Cardiac magnetic resonance imaging (MRI) for LVOT evaluation  
- Percutaneous intervention in HCM  
- Long‑term survival in HCM  
- Guideline‑based referral for septal reduction therapy.

Page 64 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- Ventricular septal myectomy  
- Transaortic approach to septal myectomy  
- Transapical approach to septal myectomy  
- Apical myectomy  
- Alcohol septal ablation (ASA)  
- Mitral valve plication  
- Anterior mitral leaflet extension  
- Subvalvular mitral apparatus reconstruction  
- Mitral valve abnormalities  
- Papillary muscle abnormalities  
- Papillary muscle morphology  
- Left ventricular hypertrophy (LVH)  
- Left ventricular outflow tract (LVOT) obstruction  
- Pulmonary hypertension  
- Atrial fibrillation (AF)  
- Residual gradients  
- Recurrent gradients  
- Hemodynamic function  
- Myocardial perfusion  
- Left ventricular relaxation  
- Prognosis  
- Genotype (sarcomeric HCM)  
- Sarcomeric human cardiomyopathy registry (SHaRE)  
- Epicardial coronary artery disease  
- Pharmacologic treatment options  
- Beta‑blockers (e.g., propranolol, nadolol)  
- Calcium‑channel blockers (e.g., verapamil, diltiazem)  
- Angiotensin II receptor blocker (losartan)  
- Angiotensin receptor blocker (valsartan)  
- Echocardiography  
- Doppler echocardiography  
- Cardiac catheterization  
- Catheter cardiovascular intervention  
- AHA/ACC/HFSA guideline for heart failure management  
- Heart failure with preserved ejection fraction (HFpEF)  
- Modified Konno procedure (high‑risk children)  
- Ventricular septal defect (VSD)  
- Myocardial metabolism  
- Randomized clinical trials  
- Meta‑analysis  
- Systematic review  
- Clinical outcomes  
- Long‑term follow‑up  
- Survival analysis  
- Risk factors  
- Prognostic predictors  
- Surgical outcomes  
- Reoperation outcomes  
- Myectomy outcomes  
- Alcohol septal ablation outcomes  

Page 65 Extracted Terms:
Hypertrophic cardiomyopathy (HCM)  
End‑stage hypertrophic cardiomyopathy  
Dilated phase of hypertrophic cardiomyopathy  
Hypokinetic hypertrophic cardiomyopathy  
Restrictive cardiomyopathy  
Heart failure  
Advanced heart failure  
Left ventricular remodeling  
Left ventricular systolic dysfunction  
Cardiopulmonary exercise testing  
Cardiac resynchronization therapy (CRT)  
Biventricular pacing  
Left ventricular assist device (LVAD)  
Mechanical circulatory support device  
Heart transplantation  
Orthotopic heart transplantation  
International Society for Heart Lung Transplantation (ISHLT) listing criteria  
Mavacamten  
Angiotensin II receptor blocker losartan  
Spironolactone  
Non‑vitamin K antagonist oral anticoagulants (NOACs)  
Anticoagulation  
Atrial fibrillation (AF)  
Thromboembolism  
Stroke  
Late gadolinium enhancement (LGE)  
Cardiovascular magnetic resonance (CMR)  
CMR assessment  
CMR risk stratification  
Molecular profiling  
Single‑nucleus profiling  
Clinical phenotype  
Prognosis  
Risk factors  
Genetics  
Cardiovascular imaging  
Ventricular remodeling  
INTERMACS  
Berlin Heart EXCOR  
COMPANION trial  
Defibrillation  
Implantable cardioverter‑defibrillator (ICD)  
Management of HCM and AF  
Stroke risk  
Anticoagulation strategies  
Clinical guidelines  
2024 Hypertrophic Cardiomyopathy Guideline  
Survival after transplantation  
Waitlist outcomes  
Cardiac outcomes  
End‑stage heart disease

Page 66 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Subclinical atrial fibrillation  
- Device‑detected atrial fibrillation  
- Ventricular tachycardia (VT)  
- Ventricular arrhythmia  
- Implantable cardioverter‑defibrillator (ICD)  
- ICD shock  
- Catheter ablation  
- Radiofrequency ablation  
- Surgical ablation of atrial fibrillation  
- Septal myectomy  
- Heart transplant  
- Beta‑blocker therapy  
- Amiodarone  
- Sotalol  
- Disopyramide  
- Dofetilide  
- Mexiletine  
- Encainide  
- Flecainide  
- Non‑vitamin K antagonist oral anticoagulant (NOAC)  
- Warfarin  
- Anticoagulation for atrial fibrillation  
- Thromboembolic risk  
- Stroke risk  
- Ventricular tachycardia suppression  
- HCM risk calculators (e.g., HCM‑Risk‑CVA)  
- Sudden cardiac death (SCD)  
- Atrial tachyarrhythmia  
- Rhythm‑control strategies  
- Device‑detected arrhythmia duration  
- Implantable cardioverter‑defibrillator programming and testing  
- Ventricular tachycardia triggers  
- Pre‑operative arrhythmia management  
- Advanced heart failure with preserved ejection fraction (HFpEF) in HCM  
- Congestive heart failure outcomes  

These terms capture the principal heart‑disease entities, arrhythmias, therapies, and risk factors referenced in the provided guideline excerpts.

Page 67 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Radiofrequency catheter ablation  
- Exercise training (structured)  
- Physical activity (moderate‑intensity, vigorous)  
- Competitive sports participation  
- Genetically inherited heart diseases  
- Long QT syndrome  
- Risk factors for sudden death  
- Cardiac arrest (sudden cardiac arrest, SCA)  
- Cardiac screening (genetic testing, imaging)  
- Cardiopulmonary exercise testing  
- Exercise intensity (MET values)  
- Exercise-induced arrhythmia  
- Cardiac rehabilitation  
- Electrophysiology interventions  
- AHA/ACC guideline for HCM  
- ESC guideline for HCM  
- Aeronautical medical certification for heart disease  
- Physical activity guidelines for Americans  
- Shared decision‑making in HCM care  
- Return‑to‑play protocols for athletes with heart disease  
- Sports‑related sudden death epidemiology  
- Structural heart disease (apical aneurysm, mid‑ventricular obstruction)  
- Inherited channelopathies (e.g., Brugada, catecholaminergic polymorphic ventricular tachycardia)  
- Cardiac genetics and mutation carriers  
- Barriers to physical activity in HCM patients  
- Emergency action plans for sudden cardiac arrest in sport.

Page 68 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Pregnancy‑related cardiac risk in HCM  
- Atrial fibrillation  
- Thromboembolism  
- Stroke  
- Mechanical heart valves  
- Anticoagulation therapy (including DOACs)  
- Valvular heart disease  
- ACC/AHA clinical practice guidelines  
- ESC guidelines for cardiovascular diseases in pregnancy  
- Obesity & cardiac remodeling in HCM  
- Exercise tolerance / capacity  
- Left ventricular morphology / wall thickness  
- Sleep‑disordered breathing (obstructive sleep apnea)  
- Nocturnal oximetry abnormalities  
- Ventricular tachycardia (nonsustained)  
- Myocardial fibrosis  
- Cardiac magnetic resonance imaging (CMR)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Sudden cardiac death (SCD) prevention  
- Genotype‑based risk stratification in HCM  
- Phenotype‑specific risk algorithms  
- Valsartan (Angiotensin II receptor blocker) for early HCM  
- Mavacamten (myosin inhibitor) for obstructive HCM  
- Aficamten (myosin inhibitor) clinical trials  
- Sarcomere contractility inhibitors  
- Early‑stage HCM biomarkers  
- Maximal left‑ventricular wall‑thickness measurement  
- HCM risk score (eg., HCM Risk‑CVA, HCM Risk‑SCD)  
- Obstructive vs. non‑obstructive HCM classification  
- Cardiogenic risk in primary prevention of cardiovascular disease  
- Sleep‑disordered breathing interaction with atrial fibrillation  
- Pregnancy‑focused obstetric–cardiologic outcomes  
- Registry data (e.g., ROPAC, SHaRE) in HCM research  
- Clinical trial design for HCM therapeutics  
- Cardio‑thoracic surgery considerations in HCM  
- Left‑ventricular hypertrophy pathophysiology  
- Genetic mutations in MYL2, sarcomeric proteins, and HCM susceptibility  

These terms capture the core heart‑disease concepts highlighted in the provided guideline excerpts.

Page 69 Extracted Terms:
Hypertrophic Cardiomyopathy  
Atrial Fibrillation  
Arrhythmia Management  
Catheter Ablation  
Pulmonary Vein Isolation  
Pulsed Field Ablation  
Genetic Variants in Cardiomyopathy  
MYH7 Gene  
Dilated Cardiomyopathy  
Late Gadolinium Enhancement  
Myocardial Scar  
Radiomics  
3‑Dimensional Strain Analysis  
Cardiac Imaging  
Electrophysiology  
Heart Failure  
Cardiomyopathy  
Cardiac Rhythm Disorders  
Ventricular Tachycardia  
Ventricular Fibrillation  
Dofetilide Therapy  
Rhythm Control  
Heart Rate Management  
Cardiovascular Genetics  
Inheritable Cardiomyopathies  
ACMG/AMP Variant Classification  
National Heart, Lung, and Blood Institute (NHLBI)  
Heart and Lung Institute (HCI)  
Hypertrophic Cardiomyopathy Registry (HCMR)  
Clinical Guidelines for HCM  
Heart and Blood Vessel Disease  
Cardiac Electrophysiology  
Catheter‑Based Ablation of Atrial Fibrillation  
Pulmonary Vein Isolation Techniques  
Myocardial Scar Heterogeneity  
Genetic Architecture of HCM  
Cardiovascular Institute  
Pediatric Electrophysiology  
Translational Research in Cardiovascular Medicine  
Cardiovascular Clinic  
Genetic Pathways in Cardiac Disease  
Cardiovascular Research Institution  
Evidence‑Based Management of HCM  
Efficacy of Rhythm‑Control Medications  
Outcomes of Ablation in HCM Patients  
Predictors of Major AF Endpoints  
Systolic Dysfunction  
Cardiac Structural Assessment  
Biomarker Analysis  
Clinical Decision Support in Cardiomyopathy  
Pharmacologic Management of Atrial Fibrillation  
Heart‑Disease Risk Factors  
Family Screening for Cardiomyopathy  
Myocardial Strain Imaging  
Late Gadolinium Enhancement Imaging  
Radiomics in Cardiac Imaging  
Heart‑Disease Genetic Counseling  
Heart‑Disease Clinical Trials  
Heart‑Disease Registry Data  
Heart‑Disease Pathophysiology  
Heart‑Disease Prognosis  
Heart‑Disease Management Strategies

Page 70 Extracted Terms:
- Hypertrophic Cardiomyopathy
- Congenital Heart Surgery
- Cardiovascular Imaging
- Clinical Cardiac Electrophysiology
- Heart Failure
- Transplantation
- Cardiovascular Medicine
- Radiology
- Pacing
- Pediatric Cardiology
- Sports Cardiology
- Cardiomyopathy Program
- Cardiovascular Research
- Heart Function
- Heart Function and Transplant Program
- Heart Failure Research
- Heart Failure and Transplantation
- Cardiovascular Research
- Cardiovascular 
- Cardiac 
- Heart Failure Programme (if inferred)

Page 71 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- HCM (Hypertrophic Cardiomyopathy)  
- Cardiology  
- Cardiovascular medicine  
- Heart  
- Cardiac cath labs (cardiac catheterization)  
- Heart rhythm  
- Heart disease management  
- Clinical guidelines for heart disease  
- Clinical trial enrolment in cardiac research  
- Cardiovascular research  
- Cardiovascular magnetic resonance (JCMR reference)  
- Heart rhythm society (HRS)  
- Pediatric & congenital electrophysiology (PACES) – related to cardiac conduction  
- National Heart, Lung, and Blood Institute (NHLBI) – heart disease funding  
- Heart disease disclosure policies (ACC/AHA)  

Page 72 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- Heart Disease  
- Heart Failure  
- Chest Pain  
- Heart Rhythm Disorders  
- Cardiomyopathy  
- Cardiac  
- Heart  
- HCM (Hypertrophic Cardiomyopathy)  
- HRS (Heart Rhythm Society)  
- HFSA (Heart Failure Society of America)  
- AHA/ACC (American Heart Association / American College of Cardiology)  
- AMSSM (American Society of Sports Medicine)  
- NIH (National Institutes of Health)  
- Heart Hospital  
- Heart Centre  
- Heart Rhythm Institute  
- National Center for Catastrophic Sports Injury Research  
- Medtronic (device manufacturer for heart conditions)  
- Abbott (device manufacturer for heart conditions)  
- Biosense Webster (device manufacturer for cardiac rhythm management)

Page 73 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- Cardiomyopathy  
- Heart Failure  
- Heart Rhythm  
- HCM Guidelines (Hypertrophic Cardiomyopathy Guideline)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- HRS (Heart Rhythm Society)

